| CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities LAK Fonkoua, O Sirpilla, R Sakemura, EL Siegler, SS Kenderian Molecular Therapy-Oncolytics 25, 69-77, 2022 | 123 | 2022 |
| SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: insights into functional evolution and human genomics R Gupta, J Charron, CL Stenger, J Painter, H Steward, TW Cook, W Faber, ... Journal of Biological Chemistry 295 (33), 11742-11753, 2020 | 57 | 2020 |
| Virus-induced genetics revealed by multidimensional precision medicine transcriptional workflow applicable to COVID-19 JW Prokop, R Shankar, R Gupta, ML Leimanis, D Nedveck, K Uhl, B Chen, ... Physiological genomics 52 (6), 255-268, 2020 | 21 | 2020 |
| SARS-CoV-2-encoded proteome and human genetics: from interaction-based to ribosomal biology impact on disease and risk processes O Sirpilla, J Bauss, R Gupta, A Underwood, D Qutob, T Freeland, C Bupp, ... Journal of Proteome Research 19 (11), 4275-4290, 2020 | 16 | 2020 |
| Sept8/SEPTIN8 involvement in cellular structure and kidney damage is identified by genetic mapping and a novel human tubule hypoxic model GR Keele, JW Prokop, H He, K Holl, J Littrell, AW Deal, Y Kim, PB Kyle, ... Scientific Reports 11 (1), 2071, 2021 | 15 | 2021 |
| CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS RL Sakemura, C Manriquez Roman, P Horvei, EL Siegler, JH Girsch, ... Blood 143 (3), 258-271, 2024 | 7 | 2024 |
| Evolutionary Landscape of SOX Genes to Inform Genotype-to-Phenotype Relationships A Underwood, DT Rasicci, D Hinds, JT Mitchell, JK Zieba, J Mills, ... Genes 14 (1), 222, 2023 | 6 | 2023 |
| Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression O Sirpilla, RL Sakemura, M Hefazi, TN Huynh, I Can, JH Girsch, ... Nature Biomedical Engineering 8 (4), 443-460, 2024 | 4 | 2024 |
| Chimeric antigen receptor engineering of mesenchymal stromal cells (CAR-MSC) enhance immunosuppression and outcomes in graft versus host disease (GvHD) preclinical models O Sirpilla, RL Sakemura, M Hefazi, JH Girsch, T Huynh, MJ Cox, ... Blood 140 (Supplement 1), 1579-1580, 2022 | 4 | 2022 |
| Identification of IL-4 as a Key Regulator of CAR T-Cell exhaustion using Functional Genomics and Correlates of the Zuma-1 clinical trial CM Stewart, MJ Cox, RL Sakemura, EJ Ogbodo, I Can, ... Blood 140 (Supplement 1), 4536-4537, 2022 | 4 | 2022 |
| CD19 antigen occupancy on cancer cells with the CD19 monoclonal antibody tafasitamab improves the activation, antitumor efficacy, and safety profile of CART19 cell therapy RL Sakemura, C Manriquez-Roman, P Horvei, MJ Cox, T Huynh, ... Blood 140 (Supplement 1), 2362-2364, 2022 | 3 | 2022 |
| IL-4 depletion leads to the improvement of CART cell therapy C Stewart, MJ Cox, R Sakemura, EJ Ogbodo, I Can, CM Roman, K Yun, ... Cancer Research 83 (7_Supplement), 1153-1153, 2023 | 2 | 2023 |
| Bioengineering mesenchymal stromal cells with chimeric antigen receptors induces superior immunosuppressive efficacy in preclinical graft versus host disease models O Sirpilla, RL Sakemura, M Hefazi, TN Huynh, JH Girsch, I Can, K Yun, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | 2 | 2023 |
| Affinity of Anti-CD19 Antibodies Determines Subsequent CART19 Activation, Apoptosis and CRS in Preclinical Models RL Sakemura, CM Roman, LK Mai, BL Kimball, T Huynh, JM Feigin, ... Blood 142, 6796, 2023 | 1 | 2023 |
| Simultaneous targeting of EphA3 on glioblastoma and tumor microenvironment to overcome resistance to CART cell therapy in brain cancer EJ Ogbodo, MW Ruff, RL Sakemura, C ManriquezRoman, T Huynh, ... Cancer Research 83 (7_Supplement), 5017-5017, 2023 | 1 | 2023 |
| Differential susceptibility to Senescence in CART cells based on Co-Stimulatory Signaling I Can, RL Sakemura, C Manriquez-Roman, O Sirpilla, CM Stewart, K Yun, ... Blood 140 (Supplement 1), 8600-8601, 2022 | 1 | 2022 |
| TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma CM Roman, MJ Cox, R Sakemura, K Yun, MM Adada, EL Siegler, ... Blood 138, 901, 2021 | 1 | 2021 |
| Bioengineering MSCs for untapped therapeutic potential O Sirpilla, SS Kenderian Immunotherapy, 1-5, 2024 | | 2024 |
| IL-4 drives exhaustion of CD8+ CART cells CM Stewart, EL Siegler, RL Sakemura, MJ Cox, T Huynh, B Kimball, L Mai, ... Nature Communications 15 (1), 7921, 2024 | | 2024 |
| OPTIMIZATION OF TSHR-CART CELL THERAPY TO TRANSLATE INTO A FIRST IN HUMAN PHASE I CLINICAL TRIAL IN METASTATIC THYROID CANCERS CM Roman, E Siegler, AA Demirer, M Pawlush, TN Huynh, LK Mai, ... Cytotherapy 26 (6), S182-S183, 2024 | | 2024 |
